Percutaneous needle-based OCT differentiates renal masses

(HealthDay)—Percutaneous needle-based optical coherence tomography (OCT) can differentiate renal masses, according to a study published in the May issue of The Journal of Urology.

Peter G.K. Wagstaff, from AMC University Hospital in the Netherlands, and colleagues performed percutaneous needle-based OCT of the kidney in patients presenting with a solid renal mass. They obtained pathology specimens as biopsies and/or resection specimens. In order to derive the attenuation coefficient (µ_OCT) values of oncocytoma and renal cell carcinoma, they correlated optical coherence tomography results of 40 patients to pathology results of the resected specimens.

The researchers found that the median µ_OCT was significantly lower for oncocytoma versus renal cell carcinoma. In receiver operating curve (ROC) analysis, a µ_OCT cutoff value of 3.8 mm⁻¹ could differentiate between oncocytoma and renal cell carcinoma with sensitivity, specificity, positive predictive value, and negative predictive value of 86, 75, 97, and 37 percent, respectively; 0.81 was the area under the ROC. The median µ_OCT was significantly lower for oncocytoma versus clear cell renal cell carcinoma and papillary renal cell carcinoma (P = 0.049 and 0.027, respectively).

"We demonstrated that the µ_OCT is significantly higher in renal cell carcinoma versus oncocytoma, with ROC analysis showing promising results for their differentiation," the authors write.

Copyright © 2016 HealthDay. All rights reserved.